1. Home
  2. FUND vs VNDA Comparison

FUND vs VNDA Comparison

Compare FUND & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

HOLD

Current Price

$8.62

Market Cap

245.4M

Sector

Finance

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$6.37

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUND
VNDA
Founded
1988
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.4M
289.0M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
FUND
VNDA
Price
$8.62
$6.37
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$14.00
AVG Volume (30 Days)
32.5K
1.3M
Earning Date
01-01-0001
10-29-2025
Dividend Yield
6.64%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
N/A
$212,074,000.00
Revenue This Year
N/A
$12.01
Revenue Next Year
N/A
$21.57
P/E Ratio
$8.33
N/A
Revenue Growth
N/A
11.12
52 Week Low
$6.75
$3.81
52 Week High
$8.47
$6.88

Technical Indicators

Market Signals
Indicator
FUND
VNDA
Relative Strength Index (RSI) 52.77 64.60
Support Level $8.65 $6.15
Resistance Level $8.95 $6.88
Average True Range (ATR) 0.12 0.41
MACD 0.01 0.14
Stochastic Oscillator 50.91 73.65

Price Performance

Historical Comparison
FUND
VNDA

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: